Last updated July 18, 2026
Key finding
A. soehngenii-treated subjects showed significantly reduced glycemic variability (1% reduction in the coefficient of variation; p = 0.01).
Daily oral supplementation with A. soehngenii improved glycemic control in prediabetic adults compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
Daily oral supplementation with A. soehngenii improved glycemic control in prediabetic adults compared to placebo.
These findings are significant as they suggest that A. soehngenii could be a viable option for improving glycemic control in prediabetic individuals, potentially preventing the progression to type 2 diabetes. Improved glycemic control and lower blood pressure can reduce the risk of cardiovascular complications, making this intervention valuable for public health.
The study's sample size and demographic diversity were not specified. Long-term effects of A. soehngenii supplementation were not assessed. The generalizability of the findings to broader populations may be limited.
Published in
Publication details and source links for this paper.
Ilias A, Julia KB, Max N, et al. Daily oral supplementation with A. soehngenii improves glycemic control in prediabetic adults. Gut Microbes. 2025;17(1):2504115. doi:10.1080/19490976.2025.2504115
A. soehngenii-treated subjects showed a 1% reduction in glycemic variability (p = 0.01).
A. soehngenii-treated subjects demonstrated a 6% reduction in overall glycemic control (p < 0.05).
A. soehngenii-treated subjects had a 1 mmol/mol reduction in HbA1c levels (p < 0.05).
Diastolic blood pressure was reduced by 3 mm Hg in A. soehngenii-treated subjects (p < 0.05).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to A. soehngenii CH-106 and Diastolic blood pressure, Glucose variability, HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
A. soehngenii CH-106
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
4
Evidence pairs
555
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
A. soehngenii CH-106 → Diastolic blood pressure
A. soehngenii CH-106 → Diastolic blood pressure
A. soehngenii CH-106 → Glucose variability
A. soehngenii CH-106 → Glucose variability
A. soehngenii CH-106 → Time to glycemic target
A. soehngenii CH-106 → Time to glycemic target
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on A. soehngenii CH-106 and Blood Pressure, A. soehngenii CH-106 and Glucose Variability.
This study contributes to the evidence on the following intervention-outcome relationships.
Supplements
Supplements
Curated evidence collections and hubs this study is part of.
All studies on A. soehngenii CH-106
Contributes to A. soehngenii CH-106 evidence base.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
All studies measuring Glucose Variability
Measures Glucose Variability as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
A. soehngenii CH-106 appears to improve Diastolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
A. soehngenii CH-106 appears to improve Glucose variability.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose variability
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
A. soehngenii CH-106 appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
A. soehngenii CH-106 appears to improve Time to glycemic target.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time to glycemic target
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
